Stephens & Co. upgraded Balchem from Equal-Weight to Overweight and set a new price target of $140.00 from $100.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/5/2025 | $162.00 | Neutral | Rothschild & Co Redburn |
| 3/8/2022 | $170.00 → $155.00 | Buy | HC Wainwright & Co. |
| 2/22/2022 | $175.00 | Neutral → Buy | Sidoti |
| 1/10/2022 | $160.00 → $170.00 | Buy | HC Wainwright & Co. |
| 11/29/2021 | $175.00 | Buy → Neutral | Sidoti |
| 8/2/2021 | $140.00 → $145.00 | Overweight → Equal-Weight | Stephens & Co. |
| 8/2/2021 | $145.00 → $160.00 | Buy | HC Wainwright & Co. |
Rothschild & Co Redburn initiated coverage of Balchem with a rating of Neutral and set a new price target of $162.00
HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $155.00 from $170.00 previously
Sidoti upgraded Balchem from Neutral to Buy and set a new price target of $175.00
MONTVALE, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2025 fiscal fourth quarter and full year ended December 31, 2025. For the quarter, the Company reported net sales of $263.6 million, net earnings of $39.2 million, adjusted EBITDA(a) of $67.9 million, and free cash flow(a) of $51.2 million. For the full year 2025, the Company reported net sales of $1.037 billion, net earnings of $154.8 million, adjusted EBITDA of $274.9 million, and free cash flow of $173.6 million. Ted Harris, Chairman, President, and CEO of Balchem said, "In the fourth quarter, Balchem's strong growth trajectory continued. We delivered record fo
MONTVALE, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Friday, February 20, 2026, at 11:00 AM Eastern Time (ET) to review fourth quarter and full year 2025 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Fourth quarter and full year 2025 results will be published prior to the market opening on Friday, February 20, 2026. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. Institutional investors, analysts and other members of the financial commu
MONTVALE, N.J., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will attend the CJS Securities 26th Annual New Ideas for the New Year Virtual Conference on January 14, 2026. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer and Allison Baurichter, Senior Director Investor Relations will attend the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art so
8-K - BALCHEM CORP (0000009326) (Filer)
8-K - BALCHEM CORP (0000009326) (Filer)
8-K - BALCHEM CORP (0000009326) (Filer)
4 - BALCHEM CORP (0000009326) (Issuer)
4 - BALCHEM CORP (0000009326) (Issuer)
4 - BALCHEM CORP (0000009326) (Issuer)
BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately. The appointment increases the size of AzurRx's Board to seven members. Ms. Coelho currently serves as the Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a commercial-stage specialty pharmaceutical company. During her more than 30-year career, Ms. Coelho has held numerous senior level financial an
MONTVALE, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2025 fiscal fourth quarter and full year ended December 31, 2025. For the quarter, the Company reported net sales of $263.6 million, net earnings of $39.2 million, adjusted EBITDA(a) of $67.9 million, and free cash flow(a) of $51.2 million. For the full year 2025, the Company reported net sales of $1.037 billion, net earnings of $154.8 million, adjusted EBITDA of $274.9 million, and free cash flow of $173.6 million. Ted Harris, Chairman, President, and CEO of Balchem said, "In the fourth quarter, Balchem's strong growth trajectory continued. We delivered record fo
MONTVALE, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Friday, February 20, 2026, at 11:00 AM Eastern Time (ET) to review fourth quarter and full year 2025 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Fourth quarter and full year 2025 results will be published prior to the market opening on Friday, February 20, 2026. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. Institutional investors, analysts and other members of the financial commu
MONTVALE, N.J., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that on December 9, 2025, its Board of Directors declared a dividend on its shares of common stock equal to $0.96 per share on the Company's issued and outstanding Common Stock, to be payable on January 20, 2026 to stockholders of record at the close of business on December 23, 2025. This dividend represents an 10.3% increase over last year's annual dividend. Ted Harris, Balchem's Chairman, President and CEO, said, "Balchem has a longstanding commitment to an annual dividend and we are pleased to announce the continuation of that commitment. This dividend represents the seventeenth consecut
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
SC 13G/A - BALCHEM CORP (0000009326) (Subject)